Sigrun Hallmeyer Selected Research

Interleukin-2 (IL2)

1/2017	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
10/2016	Sequencing of New and Old Therapies for Metastatic Melanoma.
1/2016	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sigrun Hallmeyer Research Topics

Disease

8	Melanoma (Melanoma, Malignant) 01/2021 - 01/2014
2	Neoplasms (Cancer) 01/2017 - 01/2014
1	COVID-19 02/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Atrophy 10/2018
1	Cardiotoxicity 10/2018
1	Oligohydramnios 01/2017
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2017
1	Disease Progression 10/2016
1	Colitis 01/2016
1	Brain Neoplasms (Brain Tumor) 01/2014
1	Prostatic Neoplasms (Prostate Cancer) 09/2006

Drug/Important Bio-Agent (IBA)

5	IpilimumabIBA 01/2021 - 01/2014
3	Interleukin-2 (IL2)IBA 01/2017 - 01/2016
2	VemurafenibIBA 12/2017 - 01/2014
2	Immune Checkpoint InhibitorsIBA 10/2016 - 01/2016
1	Immunoglobulin G (IgG)IBA 02/2022
1	Zoledronic Acid (Zometa)FDA Link 01/2022
1	Ibandronic Acid (Boniva)FDA Link 01/2022
1	human ERBB2 proteinIBA 01/2022
1	hydroxide ionIBA 01/2022
1	Clodronic Acid (Clodronate)IBA 01/2022
1	Diphosphonates (Bisphosphonates)IBA 01/2022
1	Denosumab FDA Link 01/2022
1	Hormones (Hormone)IBA 01/2022
1	aldesleukin (Proleukin)FDA Link 01/2021
1	pembrolizumabIBA 01/2021
1	LubricantsIBA 10/2018
1	Codon (Codons)IBA 12/2017
1	Trastuzumab (Herceptin)FDA Link 01/2017
1	talimogene laherparepvecIBA 12/2016
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2016
1	Peptides (Polypeptides)IBA 09/2006
1	prostate-specific antigen (146-154)IBA 09/2006

Therapy/Procedure

8	Therapeutics 01/2022 - 01/2014
5	Immunotherapy 01/2021 - 09/2006
1	Induced Labor 01/2017
1	Aftercare (After-Treatment) 01/2016
1	Radiotherapy 01/2014